For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and the formulated version represents a significant advancement . These groundbreaking therapies stabilize the transthyretin protein, halting its destructive build-u